Totus Medicines Inc.

Totus Medicines Inc. , based in the US, specializes in the development of innovative therapies aimed at previously untreatable diseases through advanced drug discovery technologies. Founded in 2019 and headquartered in Emeryville, California, Totus Medicines Inc. focuses on therapeutic solutions for complex diseases.

The founders, Jason Pontin, Jimmy Blair, and Neil Dhawan, were pivotal in establishing a company that has successfully completed 3 deals, with its latest being a Series B funding round on December 15, 2022, raising USD 66. 00 mn led by Data Collective and supported by investors such as Camford Capital and Northpond Ventures. The total amount raised by the company is USD 66. 00 mn.

Totus Medicines specializes in the development of innovative therapeutic solutions aimed at addressing previously untreatable diseases. Their core offerings include a proprietary high-throughput drug discovery platform that enables the identification of drug candidates at an unprecedented scale and speed. This platform leverages covalent molecules as a universal key to unlock 'undruggable' targets, significantly enhancing the potential to create effective treatments for complex conditions such as advanced forms of cancer, heart disease, and neurodegeneration. The company focuses on utilizing genomic data to design life-changing medicines, with particular emphasis on targeting the most mutated oncogenes in oncology.

Totus Medicines actively engages with a diverse client base that encompasses pharmaceutical companies, research institutions, and healthcare providers primarily in North America, Europe, and select markets across Asia. The revenue generation model for Totus Medicines is centered around partnerships and collaborations with pharmaceutical entities and research organizations. The company engages in B2B transactions, supplying its drug discovery services and technologies to its clients. These partnerships may include fee-for-service agreements, milestone payments, and revenue-sharing arrangements based on the success of developed therapeutics.

Totus Medicines is known for its flagship products tailored for oncology, which may involve subscription-based access to their drug discovery platform or milestone payments resulting from successful drug development outcomes. Specific pricing structures for their services are not disclosed, but the revenue model typically reflects the value of the innovative solutions provided in the pharmaceutical development process. In December 2023, Totus Medicines Inc. raised USD 66.

00 mn in Series B funding led by DCVC Bio, with participation from returning investors Northpond Ventures and Camford Capital, along with new investor Regents of the University of Minnesota. The funding will be utilized to expand Totus' pipeline, enhance the platform's functionality, and improve its clinical program. The company aims to develop new products for the treatment of complex diseases and plans to enhance its market presence in North America and select European markets by 2024.